Yükleniyor... / Loading...
This study evaluates a gene therapy called PF-07055480 (giroctocogene fitelparvovec), designed to produce Factor VIII, in adult men with moderately severe to severe hemophilia A. To join, patients must have been on routine Factor VIII prophylaxis and completed the lead-in study. The study is being conducted in Phase 3 and is active but not currently recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
+5
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Main inclusion Criteria * Males who have been followed on routine Factor VIII prophylaxis therapy during the lead-in study (C0371004) and have \> = 150 documented exposure days to a Factor VIII protein product * Moderately severe to severe hemophilia A (Factor VIII activity \< =1%) * Suspension of FVIII prophylaxis therapy post study drug infusion Main exclusion Criteria * Anti-AAV6 neutralizing antibodies * History of inhibitor to Factor VIII * Laboratory values at screening visit that are abnormal or outside acceptable study limits * Significant and/or unstable liver disease, biliary disease, significant liver fibrosis * Conditions associated with increased thromboembolic risk such as inherited or acquired thrombophilia, or a history of thrombotic events * Planned surgical procedure requiring Factor VIII surgical prophylactic factor treatment 12 months from screening visit * Active hepatitis B or C * Serological evidence of human immunodeficiency virus HIV-1 or HIV-2 with Cluster of Differentiation 4 positive (CD4+) cell count ≤200 mm3 and/or viral load \>20 copies/mL